Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05230810 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
A Phase 1 study of HER2-positive Metastatic Breast Cancer, sponsored by Criterium.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT05230810 is a Phase 1 study of HER2-positive Metastatic Breast Cancer that is active but no longer recruiting, run by Criterium. The registered enrollment target is 40 participants, below the 121-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05230810, a Phase 1 study of HER2-positive Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Criterium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Tucatinib
- DRUG Alpelisib
Study Locations (4)
Colorado
- University of Colorado Cancer Center - Aurora
- Cancer Care & Hematology-Fort Collins - Fort Collins
Louisiana
- Louisiana State University Health Sciences Center - New Orleans
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05230810
The ClinicalTrials.gov registry entry for NCT05230810 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT05230810 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Louisiana, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05230810 about?
NCT05230810 is a clinical study titled "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.". Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.
What is the current status of trial NCT05230810?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-08-25. Estimated completion is 2026-06-30.
What conditions does trial NCT05230810 study?
This clinical trial studies the following conditions: HER2-positive Metastatic Breast Cancer.
What interventions are being tested in trial NCT05230810?
The interventions under investigation include: Fulvestrant (DRUG), Tucatinib (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT05230810?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05230810 being conducted?
This trial has 4 study locations across Colorado, Louisiana, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing a New Imaging Agent to Identify Cancer
ACTIVE NOT RECRUITING · Phase 1
-
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.